Greiner Bio-One Subsidiary Mediscan Opens Sterilization Facility Unique in the World

The company has invested a total of EUR 14 million in the expansion. "Two technologies to sterilize and finish products will be used together in a single system at the new site. This makes us global technology leaders", explains Rainer Perneker, Division Director of Greiner Bio-One International.

Treating products with electron beams and X-ray photons at one site creates numerous advantages and synergy effects for Mediscan's customers, who include manufacturers of drugs and medical devices and plastics processors. Products that are sterilized using either technology can be sent to the same address and in the same shipment if necessary. Moreover, the system's high level of automation ensures that it sets new industry standards for accuracy, quality and throughput time.

Crucial Increase in Capacity

The site had to be expanded due to the continuous increase in production volume at Greiner Bio-One and the increasing level of third-party business at Mediscan. A new building was therefore constructed for Mediscan next to Greiner Bio-One's production plant in Kremsmünster which more than doubles the existing capacity. Sterilization is the last step in Greiner Bio-One's production chain. All medical products are treated at Mediscan before they are delivered to customers. "Mediscan's services are of crucial importance to Greiner Bio-One. We are very happy that the company's range is becoming more and more attractive to third-party customers thanks to our long-standing expertise and unique technologies", says Perneker.

Commitment to Upper Austria

Upper Austria is the innovation and technology center of the Greiner Group, which operates in 29 countries. "We are very much connected to Upper Austria. Greiner Bio-One has invested in Upper Austria over the past few years, for example in the production and research facility in Rainbach im Mühlkreis and in the logistics center in Kremsmünster. It was therefore always clear that the new sterilization facility would be built there", explains Axel Kühner, Chairman of the Management Board at Greiner Holding AG.
In addition to Kremsmünster, Mediscan operates another site in Seibersdorf. The company has a total of 40 employees and generated sales of more than EUR 8 million in 2014.

About Greiner Bio-One International GmbH

Greiner Bio-One specialises in the development, production and distribution of quality plastic products for laboratory use. The company is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic and pharmaceutical industry, and the biotechnology industry. Greiner Bio-One is split into four divisions: Preanalytics, BioScience, Diagnostics and OEM. Greiner Bio-One International GmbH generated sales of EUR 388 million in 2014 and has 1800 employees, 23 subsidiaries and numerous distribution partners in more than 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).

Greiner Bio-One GmbH – BioScience Division

Thanks to its BioScience division, Greiner Bio-One is one of the leading providers of special products for cultivating and analyzing cell and tissue cultures and microplates for high throughput screening that offer industry and the research community the quickest and most efficient active substance tests.

Greiner Bio-One GmbH – Preanalytics Division

Based on customer requests and the demands of the diagnostic market, Greiner Bio-One is developing sampling systems for blood, urine, and saliva in its Preanalytics division, which make it easier and, most importantly, safer to carry out daily routine tasks in the clinic, laboratory or in medical offices.

Greiner Bio-One GmbH – Diagnostics Division

The division has four strategic focuses in the field of diagnostics: screening test procedures for sexually transmitted diseases, hospital bugs, vaccine safety and customer-specific products. Two completely different detection systems satisfy mass analysis (screening) requirements, as well as individual analysis requirements for acute medicine.

 

For further inquiries please contact: Nick Rudge, Marketing Coordinator at Greiner Bio-One UK
Tel: +44 (0)1453 825255, e-mail: nick.rudgegbocom